ICD-10 codes for LGMD
New ICD-10 codes for limb-girdle muscular dystrophy (LGMD) became available for use in October 2022.
The ability to accurately record a patient’s LGMD subtype through specific ICD-10 codes, when possible, is an important advancement for several reasons. Adoption of the new ICD-10 codes will support clinical and research communities in ongoing efforts to:
- Understand LGMD epidemiology
- Assess natural history / disease progression of the condition
- Understand economic burden of LGMD
- Help manage care of patients
- Facilitate reimbursement and patient access when targeted therapies become available in the future
What are ICD-10 codes?
ICD-10 refers to the 10th edition of the International Statistical Classification of Diseases and Related Health Problems (ICD), a medical classification list endorsed by the World Health Organization (WHO). The ICD provides a standardized method for classifying and coding health conditions and diseases, with codes representing diagnoses, symptoms, and procedures.
ICD-10 codes are used:
- By hospitals to bill insurance companies for healthcare provided to patients
- To gather data on illnesses and track health statistics
- To inform research, such as understanding the epidemiology of a disease
What can healthcare professionals do?
Up until now, LGMD patients were likely coded under G71.0 “Muscular Dystrophy”:
- G71.00 – “Muscular dystrophy, unspecified”
- G71.09 – “Other specified muscular dystrophies”
If you have LGMD patients captured under G71.00 or G71.09, please refer to the updated ICD-10 codes to accurately capture their diagnosis at their next appointment.
What can individuals living with LGMD do?
At your next visit, speak with your physician about LGMD subtype-specific ICD-10 codes to help ensure that your diagnosis is coded properly.
ICD-10 Code Table
|Diagnosis code||Description||Subtype, if applicable|
|G71.031||Autosomal dominant LGMD||LGMD1/D|
|G71.032||Autosomal recessive LGMD due to calpain-3 dysfunction (calpainopathy)||LGMD2A/R1|
|G71.033||LGMD due to dysferlin dysfunction (dysferlinopathy)||LGMD2B/R2|
|G71.0340||LGMD due to sarcoglycan dysfunction, unspecified (sarcoglycanopathy)|
|G71.0341||LGMD due to alpha sarcoglycan dysfunction (alpha-sarcoglycanopathy)||LGMD2D/R3|
|G71.0342||LGMD due to beta sarcoglycan dysfunction (beta-sarcoglycanopathy)||LGMD2E/R4|
|G71.0349||LGMD due to other sarcoglycan dysfunction||LGMD2C/R5*
|G71.035||LGMD due to anoctamin-5 dysfunction (anoctaminopathy)||LGMD2L/R12|
|G71.038||Other LGMD**||Other autosomal recessive forms of LGMD, such as LGMD2I/R9 (caused by mutations in fukutin-related protein gene, FKRP)|
*LGMD2C/R5 is caused by mutations in the SGCG gene, which encodes gamma-sarcoglycan. LGMD2F/R6 is caused by mutations in the SGCD gene, which encodes delta-sarcoglycan.
**G71.038 is intended for all other forms of autosomal recessive LGMD. G71.039 is intended for patients that do not have a genetically confirmed LGMD diagnosis. If a patient has not yet received genetic testing to confirm their LGMD diagnosis, please visit limbgirdle.com/genetic-testing for more information.